Improved Arterial Compliance by a Novel Advanced Glycation End-Product Crosslink Breaker
By D. Kass, E. Shapiro, Miho Kawaguchi, A. Capriotti, A. Scuteri, R. Degroof, E. Lakatta. Circulation, 2001
735 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Clinical Biochemistry, Nutrition and Dietetics
View Paper: https://www.semanticscholar.org/paper/ab6969f1f4255f3b25ed2c2e8ad7082598242fde
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- E. Lakatta
- Rhian M. Touyz
- J. Forbes
- S. Laurent
- I. Wilkinson
- M. Cooper
- Ramachandran S. Vasan
- J. Cockcroft
Citations in the corpus
- The role of advanced glycation end products in progression and complications of diabetes (2008, background): “Another randomized placebo-controlled trial in hypertensive subjects showed a reduction in pulse pressure and arterial stiffness (97).”
- Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms (2017, background): “In particular, alagebrium improved endothelial function, reduced aortic stiffness, and increased vascular compliance.(47)”
- Advanced Glycation End Products and Diabetic Complications (2014, background): “AGE cross-links on collagen and elastin increase the surface area of ECM to increase the stiffness of the vasculature [14,175].”
- Mechanisms of diabetic complications. (2013, background): “This has been shown under pathological conditions to excessively cross-link the matrix resulting in stiffening (86, 120, 290).”
- Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. (2005, background): “After 56 days of treatment, ALT-711 resulted in improved total arterial compliance in aged humans with vascular stiffening (Kass et al., 2001; Susic et al., 2004).”
- Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects (2013, background): “The majority of existing drugs do not seem to lower aPWV in a blood pressure–independent manner, but longterm blockade of the renin-angiotensin system (48) and novel agents targeting elastic fiber cross-linking (49) or calcification may afford some benefit.”